THE #1 BRAND IN THE WORLD’S SECOND LARGEST AESTHETIC MARKET WITH THE MOST VERSATILE SUITE OF MEDICAL DEVICES.*
*Brazil is the second largest market in the World for “non-invasive aesthetic procedures”, according to ISAPS (International Society of Aesthetics Plastic Surgeons).
VYDENCE® comes from the portuguese word “vidência” meaning the power or gift to “see the future”;
Development, manufacturing and distribution of medical devices for aesthetic markets in dermatology, plastic surgery, phlebology and other specialties.
PROVIDES STRONG FINANCIAL SUPPORT
US-based VC fund founded in 1969 as the venture arm of the Rockefeller Family. One of lead investors in Zeltiq.
US-based healthcare VC fund with over $500M under management.
US-based VC healthcare VC fund with over $500M under management.
The reason why we’ve chosen VYDENCE®
“As a syndicate of US-led technology venture capital funds, we canvased emerging markets to identify products or companies that dominate their local markets but whose technology is World-Class. We invested in VYDENCE® because they dominate the Brazilian market with more than 7.500 systems installed, with very compelling advantages over other available products.”
Fred Aslan, MD
Executive Chairman – VYDENCE® Medical
Former investor at Venrock – led Series C in Zeltiq
Board of Directors:
THE LEADING INDUSTRY EXECUTIVES
Executive Chairman, VYDENCE® Medical
CEO, VYDENCE® Medical
General Partner, VENROCK
Partner, Aberdare Ventures
Partner, Arboretum Ventures
Born and raised in Brazil, Dr. Fred Aslan is the founder and Executive Chairman of Adavium Medical (holding company that founded VYDENCE® Medical, now the largest Brazilian aesthetic device company). Dr. Aslan also serves as President and Chief Business Officer of Vividion Therapeutics, a San Diego-based biotechnology company developing therapeutics against cancer and other medical conditions. Prior to Vividion Therapeutics, he was an investor at Venrock, one of the leading US-based venture capital funds, where he led Venrock’s investment in Zeltiq, a NASDAQ-listed medical device company that was acquired by Allergan in 2017 for more than $2 billion. Prior to Venrock, Dr. Aslan was Director of Business Development at CuraGen, a NASDAQ-listed oncology-focused biotech company, and was a strategy consultant with Boston Consulting Group (BCG). He also serves on the board of Cytrellis, a US-based esthetic device company. Dr. Aslan received a B.S. in Biology from Duke University, an M.D. from Yale School of Medicine and an M.B.A. from Harvard Business School.
André was President of INDUSTRA Technologies prior to its merger with Adavium Medical’s dermatology device division to form VYDENCE® Medical. André led INDUSTRA to become one of the leading companies in the segment – he was responsible for the development of all products in VYDENCE®’s portfolio and launched multiple LASER-based devices which are today market share leaders in Brazil. André is a mechanical engineer by training.
150+ employees dedicated to support medical practice growth
A global install base of almost 10.000 devices and growing.
Over 5.000.00 treatments performed to date.
Sold in over a dozen of countries, including United States.
VYDENCE®: A growing company
Average growth rate of 25% in 5 years
Key Company Milestones
CONTINUOUS PRODUCT LAUNCHES
ETHEREA® Users Meeting
• 100 attendees
• 13 speakers and guests
• 15 conference sessions
• 150 attendees
• 14 speakers and guest
• 15 conference sessions
• 200 attendees
• 16 speakers and guests
• 23 conference sessions
• 250 attendees
• 30 speakers and guests
• 35 conferencesessions
• 300 attendees
• 42 speakers and guests
• 33 conference sessions